A living systematic review, meta-analysis and open-data resource of randomized controlled trials of psilocybin treatment for symptoms of depression – Nature Mental Health

The living database used for this analysis can be accessed via Metapsy (docs.metapsy.org/databases/depression-psiloctr/) or via Zenodo (https://doi.org/10.5281/zenodo.15714852)⁷⁰.

Code for all analyses can be accessed on our website (sypres.io), or on our GitHub repository (https://github.com/PennLINC/sypres-docs) (release 26.0.0).

1. Proudman, D., Greenberg, P. & Nellesen, D. The growing burden of major depressive disorders (MDD): implications for researchers and policy makers. PharmacoEconomics 39, 619–625 (2021).

   Article  PubMed  PubMed Central  Google Scholar 

2. Siegel, J. S., Daily, J. E., Perry, D. A. & Nicol, G. E. Psychedelic drug legislative reform and legalization in the US. JAMA Psychiatry 80, 77–83 (2023).

   Article  PubMed  PubMed Central  Google Scholar 

3. Nutt, D., Erritzoe, D. & Carhart-Harris, R. Psychedelic psychiatry’s brave new world. Cell 181, 24–28 (2020).

   Article  PubMed  Google Scholar 

4. Quitkin, F. M., Rabkin, J. G., Ross, D. & McGrath, P. J. Duration of antidepressant drug treatment: what is an adequate trial? Arch. Gen. Psychiatry 41, 238–245 (1984).

   Article  PubMed  Google Scholar 

5. Seybert, C. et al. Quality of reporting on psychological interventions in psychedelic treatments: a systematic review. Lancet Psychiatry 12, 54–66 (2025).

   Article  PubMed  Google Scholar 

6. Norring, S. & Spigarelli, M. The promise of therapeutic psilocybin: an evaluation of the 134 clinical trials, 54 potential indications, and 0 marketing approvals on ClinicalTrials.gov. Drug Des. Devel. Ther. 18, 1143–1151 (2024).

   Article  PubMed  PubMed Central  Google Scholar 

7. Goodwin, G. M. et al. Single-dose psilocybin for a treatment-resistant episode of major depression. N. Engl. J. Med. 387, 1637–1648 (2022).

   Article  PubMed  Google Scholar 

8. Ko, K., Kopra, E. I., Cleare, A. J. & Rucker, J. J. Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis. J. Affect. Disord. 322, 194–204 (2023).

   Article  PubMed  Google Scholar 

9. Haikazian, S. et al. Psilocybin-assisted therapy for depression: a systematic review and meta-analysis. Psychiatry Res. 329, 115531 (2023).

   Article  PubMed  Google Scholar 

10. Aghajanian, S. et al. Psilocybin for major depressive disorder: an updated systematic review and meta-analysis of randomized clinical trials. J. Psychopharmacol https://doi.org/10.1177/02698811241287542 (2024).

    Article  PubMed  Google Scholar 

11. Fang, S., Yang, X. & Zhang, W. Efficacy and acceptability of psilocybin for primary or secondary depression: a systematic review and meta-analysis of randomized controlled trials. Front. Psychiatry 15, 1359088 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

12. Dawood Hristova, J. J. & Pérez-Jover, V. Psychotherapy with psilocybin for depression: systematic review. Behav. Sci. 13, 297 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

13. Li, L. J. et al. Psilocybin for major depressive disorder: a systematic review of randomized controlled studies. Front. Psychiatry. 15, 1416420 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

14. Metaxa, A. M. & Clarke, M. Efficacy of psilocybin for treating symptoms of depression: systematic review and meta-analysis. Brit. Med. J. 385, e078084 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

15. Watford, T. & Masood, N. Psilocybin, an effective treatment for major depressive disorder in adults—a systematic review. Clin. Psychopharmacol. Neurosci. 22, 2–12 (2024).

    Article  PubMed  Google Scholar 

16. Menon, V., Ramamurthy, P., Venu, S. & Andrade, C. Randomized controlled trials of psilocybin-assisted therapy in the treatment of major depressive disorder: systematic review and meta-analysis. Acta Psychiatr. Scand. https://doi.org/10.1111/acps.13778 (2024).

    Article  PubMed  Google Scholar 

17. Singleton, S. P. et al. An initiative for living evidence synthesis in clinical psychedelic research. Nat. Ment. Health 3, 3–5 (2025).

    Article  Google Scholar 

18. Ross, S. et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J. Psychopharmacol. 30, 1165–1180 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

19. Griffiths, R. R. et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial. J. Psychopharmacol. 30, 1181–1197 (2016).

    Article  PubMed  PubMed Central  Google Scholar 

20. Davis, A. K. et al. Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 78, 481–489 (2021).

    Article  PubMed  PubMed Central  Google Scholar 

21. Raison, C. L. et al. Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial. JAMA 330, 843–853 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

22. von Rotz, R. et al. Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial. eClinicalMedicine 56, 101809 (2023).

    Article  Google Scholar 

23. Back, A. L. et al. Psilocybin therapy for clinicians with symptoms of depression from frontline care during the COVID-19 pandemic: a randomized clinical trial. JAMA Netw. Open 7, e2449026 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

24. Rosenblat, J. D. et al. Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin. Med 5, 190–200.e5 (2024).

    Article  PubMed  Google Scholar 

25. Lewis, B. R. et al. Psilocybin-assisted group psychotherapy and mindfulness-based stress reduction for frontline healthcare provider COVID-19-related depression and burnout: a randomized controlled trial. PLoS Med. 22, e1004519 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

26. Luquiens, A. et al. Psilocybin in alcohol use disorder and comorbid depressive symptoms: results from a feasibility randomized clinical trial. Addiction https://doi.org/10.1111/add.70152 (2025).

    Article  PubMed  Google Scholar 

27. Rieser, N. M. et al. Psilocybin-assisted therapy for relapse prevention in alcohol use disorder: a phase 2 randomized clinical trial. eClinicalMedicine 82, 103149 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

28. Ross, M. L. et al. Psilocybin-assisted psychotherapy for depression and anxiety associated with life threatening illness: a phase 2b randomized controlled trial. Gen. Hosp. Psychiatry 96, 322–331 (2025).

    Article  PubMed  Google Scholar 

29. Grob, C. S. et al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. Arch. Gen. Psychiatry 68, 71–78 (2011).

    Article  PubMed  Google Scholar 

30. Carhart-Harris, R. et al. Trial of psilocybin versus escitalopram for depression. N. Engl. J. Med. 384, 1402–1411 (2021).

    Article  PubMed  Google Scholar 

31. Krempien, S. et al. P226. Randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of CYB003, a deuterated psilocybin analog in patients with major depressive disorder. Neuropsychopharmacology 48, 63–210 (2023).

    Google Scholar 

32. Popa-Velea, O., Gheorghe, I., Truţescu, C. & Purcărea, V. Current challenges and pitfalls in the pharmacological treatment of depression. J. Med. Life 8, 181–186 (2015).

    PubMed  PubMed Central  Google Scholar 

33. Zhdanava, M. et al. The prevalence and national burden of treatment-resistant depression and major depressive disorder in the United States. J. Clin. Psychiatry 82, 20m13699 (2021).

    Article  PubMed  Google Scholar 

34. van Elk, M. & Fried, E. I. History repeating: guidelines to address common problems in psychedelic science. Ther. Adv. Psychopharmacol. 13, 20451253231198466 (2023).

    Article  PubMed  PubMed Central  Google Scholar 

35. Lieberman, J. A. et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 353, 1209–1223 (2005).

    Article  PubMed  Google Scholar 

36. Stroup, T. S. et al. Effectiveness of olanzapine, quetiapine, risperidone, and ziprasidone in patients with chronic schizophrenia following discontinuation of a previous atypical antipsychotic. Am. J. Psychiatry 163, 611–622 (2006).

    Article  PubMed  Google Scholar 

37. Trivedi, M. H. et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am. J. Psychiatry 163, 28–40 (2006).

    Article  PubMed  Google Scholar 

38. Warden, D., Rush, A. J., Trivedi, M. H., Fava, M. & Wisniewski, S. R. The STAR*D Project results: a comprehensive review of findings. Curr. Psychiatry Rep. 9, 449–459 (2007).

    Article  PubMed  Google Scholar 

39. Miklowitz, D. J. et al. Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement Program. Arch. Gen. Psychiatry 64, 419–426 (2007).

    Article  PubMed  PubMed Central  Google Scholar 

40. Parikh, S. V., LeBlanc, S. R. & Ovanessian, M. M. Advancing bipolar disorder: key lessons from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Can. J.Psychiatry 55, 136–143 (2010).

    Article  PubMed  Google Scholar 

41. Szigeti, B. & Heifets, B. D. Expectancy effects in psychedelic trials. Biol. Psychiatry Cogn. Neurosci. Neuroimaging 9, 512–521 (2024).

    PubMed  Google Scholar 

42. Schenberg, E. E. Who is blind in psychedelic research? Letter to the editor regarding: blinding and expectancy confounds in psychedelic randomized controlled trials. Expert Rev. Clin. Pharmacol. 14, 1317–1319 (2021).

    Article  PubMed  Google Scholar 

43. Muthukumaraswamy, S. et al. Reimagining psychedelic trials: theorising a pragmatic approach to complex intervention development. OSF https://doi.org/10.31234/osf.io/caup9_v1 (2025).

44. Butler, M., Jelen, L. & Rucker, J. Expectancy in placebo-controlled trials of psychedelics: if so, so what? Psychopharmacology (Berl) 239, 3047–3055 (2022).

    Article  PubMed  PubMed Central  Google Scholar 

45. Williams, Z. J., Barnett, H. & Szigeti, B. Psychedelic therapy vs. antidepressants for the treatment of depression under equal unblinding conditions: a systematic review and meta-analysis. JAMA Psychiatry https://doi.org/10.1001/jamapsychiatry.2025.4809 (2026).

46. Hsu, T. W. et al. Comparative oral monotherapy of psilocybin, lysergic acid diethylamide, 3,4-methylenedioxymethamphetamine, ayahuasca, and escitalopram for depressive symptoms: systematic review and Bayesian network meta-analysis. Brit. Med. J. 386, e078607 (2024).

    Article  PubMed  PubMed Central  Google Scholar 

47. Hieronymus, F., López, E., Werin Sjögren, H. & Lundberg, J. Control group outcomes in trials of psilocybin, SSRIs, or esketamine for depression: a meta-analysis. JAMA Netw. Open 8, e2524119 (2025).

    Article  PubMed  PubMed Central  Google Scholar 

48. Goodwin, G. M., Malievskaia, E., Fonzo, G. A. & Nemeroff, C. B. Must psilocybin always ‘assist psychotherapy’? Am. J. Psychiatry 181, 20–25 (2024).

    Article  PubMed  Google Scholar 

49. O’Donnell, K. C. et al. Misinterpretations and omissions: a critical response to goodwin and colleagues’ commentary on psilocybin-assisted therapy. Am. J. Psychiatry 181, 74–75 (2024).

    Article  PubMed  Google Scholar 

50. Bogenschutz, M. P. Pharmacological and nonpharmacological components of psychedelic treatments: the whole is not the sum of the parts. Am. J. Psychiatry 181, 75 (2024).

    Article  PubMed  Google Scholar 

51. Schenberg, E. E., King, F., da Fonseca, J. E. & Roseman, L. Is poorly assisted psilocybin treatment an increasing risk? Am. J. Psychiatry 181, 75–76 (2024).

    Article  PubMed  Google Scholar 

52. Alpert, M. D. et al. Psychotherapy in psychedelic treatment: safe, evidence-based, and necessary. Am. J. Psychiatry 181, 76–77 (2024).

    Article  PubMed  Google Scholar 

53. Deckel, G. M., Lepow, L. A. & Guss, J. ‘Psychedelic assisted therapy’ must not be retired. Am. J. Psychiatry 181, 77–78 (2024).

    Article  PubMed  Google Scholar 

54. Earleywine, M., De Leo, J., Bhayana, D., Rajanna, B. & Scott, K. Psilocybin without psychotherapy: a cart without a horse?. Am. J. Psychiatry 181, 78–79 (2024).

    Article  PubMed  Google Scholar 

55. Goodwin, G. M., Malievskaia, E., Fonzo, G. A. & Nemeroff, C. B. Psychological support for psilocybin treatment: reply to letters on our commentary. Am. J. Psychiatry 181, 79–81 (2024).

    Article  PubMed  Google Scholar 

56. Higgins, J. P. T. et al. (eds) Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (Cochrane, 2024); https://www.cochrane.org/handbook

57. Viechtbauer, W. Bias and efficiency of meta-analytic variance estimators in the random-effects model. J. Educ. Behav. Stat. 30, 261–293 (2005).

    Article  Google Scholar 

58. Viechtbauer, W. Confidence intervals for the amount of heterogeneity in meta-analysis. Stat. Med. 26, 37–52 (2007).

    Article  PubMed  Google Scholar 

59. Knapp, G. & Hartung, J. Improved tests for a random effects meta-regression with a single covariate. Stat. Med. 22, 2693–2710 (2003).

    Article  PubMed  Google Scholar 

60. Egger, M., Smith, G. D., Schneider, M. & Minder, C. Bias in meta-analysis detected by a simple, graphical test. Brit. Med. J. 315, 629–634 (1997).

    Article  PubMed  PubMed Central  Google Scholar 

61. Pustejovsky, J. E. & Tipton, E. Meta-analysis with robust variance estimation: expanding the range of working models. Prev. Sci. 23, 425–438 (2022).

    Article  PubMed  Google Scholar 

62. Paule, R. C. & Mandel, J. Consensus values and weighting factors. J. Res. Natl Bur. Stand. 87, 377 (1982).

    Article  Google Scholar 

63. Williams, D. R., Rast, P. & Bürkner, P. C. Bayesian meta-analysis with weakly informative prior distributions. Preprint at PsyArXiv https://doi.org/10.31234/osf.io/7tbrm (2018).

64. Röver, C. et al. On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis. Res. Synth. Methods 12, 448–474 (2021).

    Article  PubMed  Google Scholar 

65. Harrer, M., Kuper, P., Sprenger, A. & Cuijpers, P. metapsyTools: Several R helper functions for the ‘Metapsy’ Database. https://tools.metapsy.org (2022).

66. Balduzzi, S., Rücker, G. & Schwarzer, G. How to perform a meta-analysis with R: a practical tutorial. Evid. Based Ment. Health 22, 153–160 (2019).

    Article  PubMed  PubMed Central  Google Scholar 

67. Viechtbauer, W. Conducting meta-analyses in R with the metafor package. J. Stat. Softw. https://doi.org/10.18637/jss.v036.i03 (2010).

68. Harrer, M., Cuijpers, P., Furukawa, T. & Ebert, D. D. Dmetar: companion R package for the guide ‘Doing Meta-Analysis in R’. http://dmetar.protectlab.org (2019).

69. Röver, C. Bayesian random-effects meta-analysis using the bayesmeta R package. J. Stat. Softw. 93, 1–51 (2020).

    Article  Google Scholar 

70. Singleton, S. P. et al. metapsy-project/data-depression-psiloctr: Version 25.1.2. Zenodo https://doi.org/10.5281/zenodo.15714852 (2025).

Download references

Author notes

1. These authors contributed equally: S. Parker Singleton, Brooke L. Sevchik.

2. These authors jointly supervised this work: J. Cobb Scott, Theodore D. Satterthwaite.

Authors and Affiliations

1. Penn Lifespan Informatics and Neuroimaging Center (PennLINC), Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

   S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey & Theodore D. Satterthwaite

2. Department of Psychiatry, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

   S. Parker Singleton, Brooke L. Sevchik, Analiese Lahey & Theodore D. Satterthwaite

3. Department of Clinical, Neuro and Developmental Psychology, WHO Collaborating Centre for Research and Dissemination of Psychological Interventions, Vrije Universiteit Amsterdam, Amsterdam, the Netherlands

   Pim Cuijpers & Mathias Harrer

4. Babeș-Bolyai University, Ciuj-Napoca, Romania

   Pim Cuijpers

5. Amsterdam Public Health Research Institute, Amsterdam University Medical Centre, Amsterdam, the Netherlands

   Mathias Harrer

6. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN, USA

   Megan T. Jones & Simon N. Vandekar

7. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA

   Sandeep M. Nayak & Eric C. Strain

8. Departments of Anesthesiology and Perioperative Medicine and Neurology, University of Rochester School of Medicine and Dentistry, Rochester, NY, USA

   Robert H. Dworkin

9. Department of Psychiatry, Brain Behavior Laboratory, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA

   J. Cobb Scott

10. VISN4 Mental Illness Research, Education and Clinical Center, Crescenz VA Medical Center, Philadelphia, PA, USA

    J. Cobb Scott

11. Penn-CHOP Lifespan Brain Institute, Perelman School of Medicine, Children’s Hospital of Philadelphia Research Institute, Philadelphia, PA, USA

    Theodore D. Satterthwaite

Contributions

S.P.S., B.L.S., S.M.N., E.C.S., S.N.V., R.H.D., J.C.S. and T.D.S. conceptualized and pre-registered the study. S.P.S., B.L.S. and A.L. performed literature screening and data extraction. S.P.S. and B.L.S. performed the analysis. S.N.V., M.T.J. and M.H. provided statistical support. M.H. and P.C. provided administrative support for the living database and meta-analytic dashboard via Metapsy. S.P.S., B.L.S., J.C.S. and T.D.S. drafted the original manuscript. T.D.S. obtained funding. T.D.S. and J.C.S. provided supervision. All authors reviewed the manuscript, provided feedback and approved the final version.

Corresponding authors

Correspondence to S. Parker Singleton or Theodore D. Satterthwaite.

Competing interests

Over the past 3 years, E.C.S. has had grant funding to his institution from NIH; editing payments from Wolters–Kluwer; consulting fees from Eli Lilly and Company; medical devices supplied to his institution for his research by Masimo; and he has conducted medical–legal consultations. He also has served on the board of directors (unpaid) for a treatment program, Ashley Addiction Treatment. S.M.N. is a co-investigator on a Usona Institute sponsored trial of psilocybin for major depressive disorder. R.H.D. is the director and chair of the ACTTION management committee that funded this study and, since 1 January 2021, has received research grants and contracts from the US FDA and the US NIH, and compensation for serving on advisory boards or consulting on clinical trial methods from Acadia, Akigai, Allay, AM-Pharma, Analgesic Solutions, Beckley, Biogen, Biosplice, Bsense, Cardialen, Chiesi, Clexio, Collegium, CombiGene, Confo, Contineum, Eccogene, Editas, Eli Lilly, Emmes, Endo, Epizon, Ethismos (equity), Exicure, GlaxoSmithKline, Glenmark, Gloriana, JucaBio, Kriya, Mainstay, Merck, Mind Medicine (also equity), NeuroBo, Noema, OliPass, Orion, Oxford Cannabinoid Technologies, Pfizer, Q-State, Regenacy (also equity), Rho, Salvia, Sangamo, Semnur, SIMR Biotech, Sinfonia, SK Biopharmaceuticals, Sparian, SPM Therapeutics, SPRIM Health, Tiefenbacher, Validae, Vertex, Viscera and WCG. The other authors declare no competing interests.

Peer review information

Nature Mental Health thanks Joshua Black, Yan Liu and Richard J. Zeifman for their contribution to the peer review of this work. Peer reviewer reports are available.

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions